Biotech Values

[DewDiligence]

Is IMCL a fair comparator [to DNDN]?

If you’re referring to the value LLY paid in its buyout of IMCL, the answer (IMO) is No for two main reasons:

1. It will take several years at least for Provenge to attain the sales that Erbitux is generating (if it ever does).

2. DNDN does not have anywhere near as robust a pipeline as IMCL had at the time of the buyout by LLY.